Abdakibart 在治疗 HS 的 II 期研究中显示早期显著疗效
Abdakibart Shows Strong Early Efficacy in Hidradenitis Suppurativa
在治疗 HS 的 II 期研究中,IL-1 beta 抑制剂 abdakibart 达到了 43% 的 HiSCR75 有效率,显著优于安慰剂组,且安全性良好。
展示了 IL-1 beta 抑制剂 abdakibart 在治疗 HS 的早期显著疗效,为长期疗效观察提供了基础。
— Phase II LOTUS data suggest IL-1 beta inhibition could become an important new approach
by Gregory Laub, Senior Director, Video, MedPage Today
November 4, 2026 • 3 min read
Phase II findings presented at the European Academy of Dermatology and Venereology meeting in Vienna showed promising early efficacy with abdakibart, an investigational interleukin (IL)-1 beta inhibitor, in patients with hidradenitis suppurativa (HS).
In this exclusive MedPage Today video, Martina J. Porter, MD, of Beth Israel Deaconess Medical Center in Boston, discusses the week-16 LOTUS trial results, including Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) rates, early separation from placebo, the study's safety profile, and what the findings may mean as the drug moves into phase III.
Following is a transcript of her remarks:
I was fortunate to present the phase II findings for the abdakibart study, which was by Avalo Therapeutics. Abdakibart is an IL-1 beta inhibitor. And what we showed was the week-16 or the primary endpoint results for the study. And this was one of the largest studies that we've seen for phase II to date. There were over 240 patients, about 80 in each arm, and there were two different abdakibart doses and then a placebo group.
The key point here was that HiSCR75, which is our higher depth of response, it was about 43% of patients in both of the dosing arms that achieved HiSCR75 compared to about 25% of placebo patients. And this is one of the highest, I would say, efficacy endpoints that we've seen to date for any HS phase II study. And I think it really validates that this is a novel mechanism that will probably be involved in treating HS going forward.
And I think some of the other important things, too, that we found were that there was actually quite an early split between the drug arms and the placebo group. So even as early as week 4, there was a difference in almost all the endpoints that we were talking about for the study.
Also for the 16 weeks, there were almost no safety findings at all for this IL-1 beta, which is actually very promising. A lot of times we get really concerned about HS patients, who have so many comorbidities, but there weren't any increased infection risks, for example. There were some injection site reactions, but they happened across all the groups, both the placebo and the abdakibart arms, to the same degree. And the most common side effects that we saw were things that are probably unlikely related to the drug, like headaches. So I think in terms of safety profiles, which are really important to dermatologists, this was quite clean for the 16 weeks.
So I think the important implications of this is that we'll see this molecule move into phase III and we'll also be able to see over a longer-term period -- so not just 16 weeks -- how it performs. And historically for all of our drugs in HS, we really like to see key differentiation and efficacy endpoints and clean safety profiles at week 16. But as we know for HS in general, it's also a lot about how these patients do long term at 6 months and 12 months and even longer because a lot of the times what we see is continued improvement in their disease severity over these periods, especially after we move out of the placebo response.
来源:MedPage Today · medpagetoday.com